Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Decode Slide 9.8 Percent on News of Poor Q4 Earnings, Revenue Growth

NEW YORK, March 4 (GenomeWeb News) - Shares in Decode Genetics were down 9.76 percent, or $.61, at $5.64 in mid-afternoon trading after the company posted a slight decrease in fourth-quarter revenues atop nearly doubled net losses.


As GenomeWeb News reported this morning, total revenues for the three-month period ended Dec. 31, 2004, fell to $11.2 million from $11.7 million during the same period a year ago.


R&D expenses increased to $8.7 million from $5.8 million during the fourth quarter of 2003. This increase was mainly due to costs associated with clinical trials for two compounds, according to Decode.


Decode's net loss for the quarter swelled to $19.4 million, or $.36 per share, from $10.6 million, or $.20 per share, during the same period in 2003. This steep increase resulted from costs of clinical trials, debt service, and the impact of foreign exchange fluctuations, according to the company.


As of Dec. 31, 2004, Decode had $198.3 million in cash and investments, including restricted cash, cash equivalents, marketable securities, and other investments.

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.